Torii Pharmaceutical Co Ltd
TSE:4551
Torii Pharmaceutical Co Ltd
Total Liabilities & Equity
Torii Pharmaceutical Co Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Torii Pharmaceutical Co Ltd
TSE:4551
|
Total Liabilities & Equity
¥140.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Total Liabilities & Equity
¥15.1T
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
12%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Total Liabilities & Equity
¥3.4T
|
CAGR 3-Years
17%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Total Liabilities & Equity
¥3.7T
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Total Liabilities & Equity
¥2.1T
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Total Liabilities & Equity
¥3.5T
|
CAGR 3-Years
14%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
Torii Pharmaceutical Co Ltd
Glance View
Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.
See Also
What is Torii Pharmaceutical Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
140.7B
JPY
Based on the financial report for Dec 31, 2024, Torii Pharmaceutical Co Ltd's Total Liabilities & Equity amounts to 140.7B JPY.
What is Torii Pharmaceutical Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
4%
Over the last year, the Total Liabilities & Equity growth was 5%. The average annual Total Liabilities & Equity growth rates for Torii Pharmaceutical Co Ltd have been 2% over the past three years , and 4% over the past ten years .
You don't have any saved screeners yet